PRTK News and Press, Paratek Pharmaceuticals Inc. From 06/01/22

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gove...

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q1 2022 Earnings Call Transcript

The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Paratek Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

Paratek Pharmaceuticals, Inc. (PRTK) Q1 2022 Earnings Conference Call May 04, 2022, 4:30 PM ET Company Participants Evan Loh - CEO Sarah Higgins - Vice President Finance Controller Adam Woodrow - President and Chief Commercial Officer Randy Brenner - Chief Development and Regulatory Officer C...

Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q1 GAAP EPS of -$0.35 in-line. Revenue of $24.86M (+51.3% Y/Y) misses by $2.29M. Anticipates its existing cash, cash equivalents and marketable securities of $79.1 million as of March 31, 2022, provides for a cash runway through the en...

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON...

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022. The audio webcas...

Gainers: Biodesix  (BDSX) +71%. Aeglea BioTherapeutics (AGLE) +37%. Rubius Therapeutics  (RUBY) +9%. ASML Holding  (ASML) +6%. Arcturus Therapeutics Holdings  (ARCT) +5%. Losers: Lyra Therapeutics (LYRA) -6%. Hyzon Motors (HYZN) -5%. Paratek P...

Paratek Pharmaceuticals, Inc. (PRTK) Q4 2021 Earnings Conference Call March 14, 2022 08:30 ET Company Participants Sarah Higgins - Vice President, Finance, Controller and Principal Accounting Officer Evan Loh - Chief Executive Officer Adam Woodrow - President and Chief Commercial Officer Rand...